(EMAILWIRE.COM, November 04, 2009 ) New York, NY - MabCure has invented a brilliant new way to spot and successfully “mark” cancer cells at their earliest stage, so that they literally stand out, and can then be eliminated. The opportunity is so immense, some analysts predict the market for this type of therapy and approach can reach $22 billion per year, with an annual growth rate of 30%.

The Company has developed a series of antibodies that can mark cancer cells at their earliest stages. I’m going to assume that your knowledge of medical terms equals mine—you need things explained so you can understand them. An antibody is simply a protein molecule that attaches itself to a cancer cell so the cancer cell can then be found. Think of the antibody as a friend planting a bright orange “flag” in the target so it can be destroyed using existing treatments. This extremely specific, safe, no-side-effects targeting of cancer cells has huge benefits.

The Truth About Chemotherapy

The most widely accepted option we have today for killing these cells is Chemotherapy, a non- specific method of attack. This simply means that it destroys all the cells it touches, including healthy ones, weakening the immune system. This is one reason why patients get so sick, and why Chemotherapy is so ineffective. Yet, many in the medical community admit, “When a family member gets sick, the family expects us to do something. This is the best we have at the moment.”

Chemotherapy is the country’s most popular way of “fighting back.” However, the statistics, are truly appalling. Chemotherapy works by targeting ALL cells, including the healthy ones. Here’s what experienced doctors and institutions report…

• Dr. John Diamond says it might work 7% of the time: “Chemotherapy’s success record is poor. It can achieve remissions in about 7% of all human cancers. This type of survival is not the same as a cure or even restored quality of life.”

• Chemotherapists admit that they wouldn’t take chemotherapy — Dr. Mercola reports, “It’s especially telling that in a number of surveys, most chemotherapists have said that they would not take chemotherapy themselves or recommend it for their families.”

• John Hopkins University calls it a real failure: “Destroying cells with whole-body chemotherapy has a dismal record…”

• Dr. Ulrich Abel reports on the “appalling” results: “Success of most chemotherapy is appalling. There is no scientific evidence for its ability to extend in any appreciable way the lives of patients…”

• Dr. Ralph Moss says there’s no proof it works: “There is no proof that chemotherapy in the vast majority of cases actually extends life…”

• The non-profit medical organization, Alternative Medicine says it will kill you first: “Chemotherapy strong enough to kill the cancer would have to be strong enough to kill us first.”

Compare this approach to the one MabCure (MBCI) invented. The MabCure breakthrough can target only cancer cells for elimination and there are NO terrible side effects like chemotherapy which poisons every cell, including healthy ones. This is very important because it gives a sense just how valuable MabCure’s discovery is.

Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated seven thousand five hundred dollars for this advertising effort. Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately. Anyone not wishing to receive future Keros Capital Investor Reports should email us at opt-out@keroscapital.com

Contact Information:
MabCure Inc.
Jim Mav
Tel: 908-464-1747
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.